Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 7/20 | 0.44 |
| ▸ | PRKCI | P41743 | 9/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | YTHDF3 | Q7Z739 | 2/20 | 0.33 |
| ▸ | YTHDF1 | Q9BYJ9 | 2/20 | 0.33 |
| ▸ | YTHDF2 | Q9Y5A9 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933189 | 0.86 | YTHDC1 (0.44) | YTHDC1PRKCIXDHPDE2AYTHDF3 | |
| SCHEMBL30677310 | 0.83 | PRKCI (0.39) | YTHDC1PRKCIPOLBMAPT | |
| SCHEMBL2920664 | 0.80 | PRKCI (0.48) | PRKCI | |
| SCHEMBL7679038 | 0.76 | YTHDC1 (0.36) | YTHDC1XDHPDE2AYTHDF3YTHDF1 | |
| SCHEMBL29999199 | 0.76 | GPR35 (0.32) | PRKCI | |
| SCHEMBL1284962 | 0.76 | GPR35 (0.32) | PRKCI | |
| SCHEMBL7684270 | 0.75 | ALDH1A1 (0.44) | PRKCIMAPTHTT | |
| SCHEMBL1899418 | 0.74 | EGFR (0.40) | PRKCIMAPTHTT | |
| SCHEMBL1899420 | 0.74 | EGFR (0.40) | PRKCIMAPTHTT | |
| SCHEMBL1895629 | 0.73 | PDE5A (0.52) | PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | YTHDC1 2851/4885PRKCI 3526/4885XDH 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.